Gilead to introduce single tablet regimen for treatment of HIV

Dr. John Martin, Chairman and CEO of Gilead, predicted a strong outlook for 2011.  In his presentation at JPM Conference in SF, Dr. Martin alluded to their strong pipeline of products with 13 products currently on the market.  Gilead recently invested in 2 biotechs, CGI Pharma acquired for $120M and Arresto Bioscience acquired for $225M.  The company goal is introduction of single tablet regimen for HIV in the market, by the end of 2011 and treatment regimen for Hepatitis C.


, ,

  1. Leave a comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: